# Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

> **NCT04776239** · PHASE1,PHASE2 · COMPLETED · sponsor: **Joshua M Hare** · enrollment: 26 (actual)

## Conditions studied

- Diabetes Mellitus
- Ischemic Heart Disease

## Interventions

- **DRUG:** 100 million Allogeneic Mesenchymal Human Stem Cells
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04776239
- **Lead sponsor:** Joshua M Hare
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-16
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-08-26
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776239, "Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04776239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*